Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping

Daniel Sado(Marks and Spencer (United Kingdom)), Steven K White(Marks and Spencer (United Kingdom)), Stefan K. Piechnik(Marks and Spencer (United Kingdom)), Sanjay M Banypersad(Marks and Spencer (United Kingdom)), Thomas A. Treibel(Marks and Spencer (United Kingdom)), Gabriella Captur(Marks and Spencer (United Kingdom)), Marianna Fontana(Marks and Spencer (United Kingdom)), Viviana Maestrini(Marks and Spencer (United Kingdom)), Andrew Flett(Marks and Spencer (United Kingdom)), Matthew D. Robson(Marks and Spencer (United Kingdom)), Robin Lachmann(Marks and Spencer (United Kingdom)), Elaine Murphy(Marks and Spencer (United Kingdom)), Atul Mehta(Marks and Spencer (United Kingdom)), Derralynn Hughes(Marks and Spencer (United Kingdom)), Stefan Neubauer(Marks and Spencer (United Kingdom)), Perry Elliott(Marks and Spencer (United Kingdom)), James Moon(Marks and Spencer (United Kingdom))
Circulation Cardiovascular Imaging
April 6, 2013
Cited by 528Open Access
Full Text

Abstract

BACKGROUND: Anderson-Fabry disease (AFD) is a rare but underdiagnosed intracellular lipid disorder that can cause left ventricular hypertrophy (LVH). Lipid is known to shorten the magnetic resonance imaging parameter T1. We hypothesized that noncontrast T1 mapping by cardiovascular magnetic resonance would provide a novel and useful measure in this disease with potential to detect early cardiac involvement and distinguish AFD LVH from other causes. METHODS AND RESULTS: Two hundred twenty-seven subjects were studied: patients with AFD (n=44; 55% with LVH), healthy volunteers (n=67; 0% with LVH), patients with hypertension (n=41; 24% with LVH), patients with hypertrophic cardiomyopathy (n=34; 100% with LVH), those with severe aortic stenosis (n=21; 81% with LVH), and patients with definite amyloid light-chain (AL) cardiac amyloidosis (n=20; 100% with LVH). T1 mapping was performed using the shortened modified Look-Locker inversion sequence on a 1.5-T magnet before gadolinium administration with primary results derived from the basal and midseptum. Compared with health volunteers, septal T1 was lower in AFD and higher in other diseases (AFD versus healthy volunteers versus other patients, 882±47, 968±32, 1018±74 milliseconds; P<0.0001). In patients with LVH (n=105), T1 discriminated completely between AFD and other diseases with no overlap. In AFD, T1 correlated inversely with wall thickness (r=-0.51; P=0.0004) and was abnormal in 40% of subjects who did not have LVH. Segmentally, AFD showed pseudonormalization or elevation of T1 in the left ventricular inferolateral wall, correlating with the presence or absence of late gadolinium enhancement (1001±82 versus 891±38 milliseconds; P<0.0001). CONCLUSIONS: Noncontrast T1 mapping shows potential as a unique and powerful measurement in the imaging assessment of LVH and AFD.


Related Papers

No related papers found

Powered by citation graph analysis